TG Therapeutics to present new BRIUMVI data on multiple sclerosis at 2026 CMSC meeting

TG Therapeutics announced presentations of new data on BRIUMVI (ublituximab-xiiy) for relapsing multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers meeting. Data from the ongoing ENABLE Phase 4 study show significant patient-reported improvements and strong disease control, complementing prior Phase 3 ULTIMATE trial results. Presentations will highlight BRIUMVI's efficacy, tolerability, and one-hour infusion benefits, supporting its differentiated treatment profile. The event is scheduled for May 27-29, 2026, in Charlotte, N.C., with detailed data available on TG's website.